- PN: B111360
45x Ab-conjugated beads (S4P8- Human GDNF Ab-bead). PN: B111360A. One vial containing 100 µL of anti-human GDNF conjugated to AimPlex Bead S4P8.
25x Biotin-detection Ab (Human GDNF Biotin-dAb). PN: B111360B. One vial containing 100 µL of biotinylated anti-Human GDNF.
Lyophilized Standard Mix - Human GDNF. PN: B111360S. One vial containing lyophilized GDNF.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human Human GDNF/ATF-1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 15 pg/mL
LLOQ: < 40 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Sample volume: 15 µL/test
Glial cell-derived neurotrophic factor (GDNF) is a protein that potently promotes the survival of many types of neurons. It signals through GFRα receptors, particularly GFRα1. The recombinant form of this protein has been shown to promote the survival and differentiation of dopaminergic neurons in culture, and to prevent apoptosis of motor neurons induced by axotomy. The most prominent feature of GDNF is its ability to support the survival of dopaminergic and motorneurons. These neuronal populations die in the course of Parkinson's disease and amyotrophic lateral sclerosis (ALS). GDNF also regulates kidney development and spermatogenesis, and it affects alcohol consumption. GDNF has regenerative properties for brain cells and showed potential as treatment for Parkinson's disease. Diseases associated with GDNF include Hirschsprung Disease 3 and Congenital Central Hypoventilation Syndrome.
1. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (May 1993). "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons". Science. 260 (5111): 1130–2. doi:10.1126/science.8493557. PMID 8493557.
2. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D (Jun 2008). "GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse". Proceedings of the National Academy of Sciences of the United States of America. 105 (23): 8114–9. doi:10.1073/pnas.0711755105. PMC 2423415. PMID 18541917.
3. Cik M, Masure S, Lesage AS, Van Der Linden I, Van Gompel P, Pangalos MN, Gordon RD, Leysen JE (Sep 2000). "Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions". The Journal of Biological Chemistry. 275 (36): 27505–12. doi:10.1074/jbc.M000306200. PMID 10829012.
4. He DY, Ron D (2006). "Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine". FASEB Journal. 20 (13): 2420–2. doi:10.1096/fj.06-6394fje. PMID 17023388.
5. Carnicella S, He DY, Yowell QV, Glick SD, Ron D (2010). "Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration". Addiction Biology. 15 (4): 424–33. doi:10.1111/j.1369-1600.2010.00251.x. PMC 3783954. PMID 21040239.